- Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results
- Theriva™ Biologics hablará sobre el diseño del ensayo VIRAGE, un estudio clínico de fase 2b de VCN-01 administrado sistémicamente en combinación con quimioterapia para el adenocarcinoma pancreático ductal, en la Reunión Anual de la Sociedad Americana de Oncología Clínica (ASCO) de 2024
- Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Theriva™ Biologics anuncia datos de primera línea positivos del ensayo de fase 1 patrocinado por investigadores de VCN-01 por vía intravítrea en pacientes pediátricos con retinoblastoma refractario
- Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma
- Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting
- Theriva™ Biologics presentará datos preclínicos que apoyan la sinergia potencial entre el VCN-01 y los regímenes de quimioterapia de primera línea contra el cáncer de páncreas en la 27ª Reunión Anual de la Sociedad Americana de Terapia Celular y Genética
- Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting
- Theriva™ Biologics anuncia su presentación en la 27ª Reunión Anual de la Sociedad Americana de Terapia Celular y Génica
- Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
More ▼
Key statistics
On Wednesday, Theriva Biologics Inc (TOVX:ASQ) closed at 0.418, 111.97% above the 52 week low of 0.1972 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.397 |
---|---|
High | 0.44 |
Low | 0.397 |
Bid | 0.401 |
Offer | 0.43 |
Previous close | 0.40 |
Average volume | 90.73k |
---|---|
Shares outstanding | 17.15m |
Free float | 16.82m |
P/E (TTM) | -- |
Market cap | 6.86m USD |
EPS (TTM) | -1.15 USD |
Data delayed at least 15 minutes, as of May 08 2024.
More ▼